Literature DB >> 15881424

Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1.

Giovanni Ambrosino1, Sergio Varotto, Stephen C Strom, Graziella Guariso, Elisa Franchin, Diego Miotto, Luciana Caenazzo, Stefano Basso, Paolo Carraro, Maria Luisa Valente, Davide D'Amico, Lucia Zancan, Lorenzo D'Antiga.   

Abstract

Crigler-Najjar syndrome type 1 (CN1) is an inherited disorder characterized by the absence of hepatic uridine diphosphoglucuronate glucuronosyltransferase (UDPGT), the enzyme responsible for the conjugation and excretion of bilirubin. We performed allogenic hepatocyte transplantation (AHT) in a child with CN1, aiming to improve bilirubin glucuronidation in this condition. A 9-year-old boy with CN1 was prepared with plasmapheresis and immunosuppression with prednisolone and tacrolimus. When a graft was made available, 7.5 x 10(9) hepatocytes were isolated and infused into the portal vein percutaneously. After 2 weeks phenobarbitone was added to promote the enzymatic activity of UDPGT of the transplanted hepatocytes. Nocturnal phototherapy was continued throughout the studied period. Total bilirubin was considered a reliable marker of allogenic cell function. There was no significant variation of vital signs nor complications during the infusion. Mean +/- SD bilirubin level was 530 +/- 38 micromol/L before and 359 +/- 46 micromol/L after AHT (t-test, p < 0.001). However, the introduction of phenobarbitone was followed by a drop of tacrolimus level with increase of alanine aminotransferase (ALT) and increase of bilirubin. After standard treatment of cellular rejection bilirubin fell again but from then on it was maintained at a greater level. After discharge the patient experienced a further increase of bilirubin that returned to predischarge levels after readmission to the hospital. This was interpreted as poor compliance with phototherapy. Only partial correction of clinical jaundice and the poor tolerability to nocturnal phototherapy led the parents to refuse further hepatocyte infusions and request an orthotopic liver transplant. After 24 months the child is well, with good liver function on tacrolimus and prednisolone-based immunosuppression. Isolated AHT, though effective and safe, is not sufficient to correct CN1. Maintenance of adequate immunosuppression and family compliance are the main factors hampering the success of this procedure.

Entities:  

Mesh:

Year:  2005        PMID: 15881424     DOI: 10.3727/000000005783983250

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  50 in total

Review 1.  The possible use of stem cells in regenerative medicine: dream or reality?

Authors:  Sabrina Ehnert; Matthias Glanemann; Andreas Schmitt; Stephan Vogt; Naama Shanny; Natascha C Nussler; Ulrich Stöckle; Andreas Nussler
Journal:  Langenbecks Arch Surg       Date:  2009-07-31       Impact factor: 3.445

2.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

3.  Hepatocyte transplantation.

Authors:  Ragai R Mitry; Robin D Hughes; Anil Dhawan
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 4.  Human hepatocyte transplantation: current experience and future challenges.

Authors:  Anil Dhawan; Juliana Puppi; Robin D Hughes; Ragai R Mitry
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

5.  How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology?

Authors:  Marco Carbone; Jan Lerut; James Neuberger
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 6.  Stem cells for liver repopulation.

Authors:  Alejandro Soto-Gutierrez; Nalu Navarro-Alvarez; Hiroshi Yagi; Martin L Yarmush
Journal:  Curr Opin Organ Transplant       Date:  2009-12       Impact factor: 2.640

Review 7.  Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.

Authors:  Philippe-A Lysy; Mustapha Najimi; Xavier Stephenne; Annick Bourgois; Francoise Smets; Etienne-M Sokal
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 8.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

9.  mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.

Authors:  Christina L Avila; Jason M Zimmerer; Steven M Elzein; Thomas A Pham; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

10.  Prospects for Induced Phiripotent Stem Cell-Derived Hepatocytes in Cell Therapy.

Authors:  Masaya Iwamuro; Javed M Shahid; Kazuhide Yamamoto; Naoya Kobayashif
Journal:  Cell Med       Date:  2011-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.